New York State Common Retirement Fund Sells 7,091 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

New York State Common Retirement Fund lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 32.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,993 shares of the company's stock after selling 7,091 shares during the period. New York State Common Retirement Fund owned 0.05% of Krystal Biotech worth $1,860,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in KRYS. Vanguard Group Inc. grew its holdings in shares of Krystal Biotech by 40.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company's stock worth $278,416,000 after purchasing an additional 693,852 shares during the period. Jennison Associates LLC increased its position in shares of Krystal Biotech by 112.5% in the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company's stock worth $89,862,000 after acquiring an additional 383,495 shares in the last quarter. Fred Alger Management LLC raised its stake in shares of Krystal Biotech by 4,608.6% in the 3rd quarter. Fred Alger Management LLC now owns 167,485 shares of the company's stock valued at $19,428,000 after acquiring an additional 163,928 shares during the period. TimesSquare Capital Management LLC acquired a new position in shares of Krystal Biotech during the 3rd quarter valued at $14,272,000. Finally, Schonfeld Strategic Advisors LLC boosted its position in Krystal Biotech by 356.8% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 83,635 shares of the company's stock worth $9,702,000 after purchasing an additional 65,325 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on KRYS shares. Citigroup raised their price objective on Krystal Biotech from $160.00 to $195.00 and gave the company a "buy" rating in a research report on Tuesday, February 27th. Guggenheim raised their target price on Krystal Biotech from $130.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. Stifel Nicolaus restated a "buy" rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. HC Wainwright reissued a "buy" rating and set a $200.00 target price on shares of Krystal Biotech in a research report on Monday. Finally, William Blair reaffirmed an "outperform" rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $171.00.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares of the company's stock, valued at $265,138,786.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CAO Kathryn Romano sold 5,000 shares of Krystal Biotech stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company's stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,087 shares of company stock valued at $6,210,591. Corporate insiders own 14.10% of the company's stock.

Krystal Biotech Stock Up 0.7 %

Shares of KRYS traded up $1.06 during midday trading on Thursday, hitting $158.74. The company had a trading volume of 197,304 shares, compared to its average volume of 361,986. Krystal Biotech, Inc. has a 52 week low of $86.03 and a 52 week high of $189.97. The company's 50 day moving average price is $168.75 and its 200 day moving average price is $134.44. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of 84.89 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The business had revenue of $45.25 million during the quarter, compared to analysts' expectations of $47.37 million. The firm's quarterly revenue was up 452400.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.76) EPS. Equities analysts anticipate that Krystal Biotech, Inc. will post 1.82 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).